Sign in Subscribe
Vaccines

Mentor Capital Enters Medical Investments Portfolio with COVID-19 Focus

Strategic Insights

— 1 min read

Mentor Capital, a company known for financially supporting leading-edge immunotherapies in the fight against cancer, has expanded its portfolio to include vaccine manufacturers and associated medical companies involved in the fight against SARS-CoV-2. The company's initial investments are in Pfizer, Moderna, BioNTech, and AstraZeneca, with a focus on private companies seeking public market liquidity. This move aligns with Mentor's history of supporting cutting-edge medical treatments, and it also sponsors a non-profit initiative, Antibody Badge, which provides COVID-19 antibody lapel pins to individuals who have received the vaccine.

Key Takeaways:

  • Mentor Capital has added a business segment focused on vaccine and medical companies involved in the fight against SARS-CoV-2, with initial investments in Pfizer, Moderna, BioNTech, and AstraZeneca.
  • The majority of medical segment purchases are targeted toward private companies supporting the battle against COVID-19, with funding sourced from common shares, accredited investors, and debt.
  • The company's non-profit initiative, Antibody Badge, provides COVID-19 antibody lapel pins to individuals who have received the vaccine, with the goal of promoting peace of mind and facilitating social interactions.
  • Anecdotal survey suggests that approximately 24% more people would get the vaccine if the Antibody Badge lapel pin could be worn in lieu of a mask in casual settings.
  • Mentor Capital's business move into the COVID-19 arena is a natural extension of its long history of financially supporting leading-edge immunotherapies in the fight against cancer.
  • The company's primary goal is to assist private companies and their founders in meeting their liquidity and financial objectives, while adding protection for investors and incubating private companies.
  • Mentor Capital seeks to support the development of innovative medical treatments and promote the transition of private companies into public realm.

Statistics:

  • Approximately 90%-95% effective SARS-CoV-2 vaccines are available from Pfizer/BioNTech, Moderna, and AstraZeneca.
  • 24% more people would get the vaccine if the Antibody Badge lapel pin could be worn in lieu of a mask in casual settings.
  • Mentor Capital has a history of supporting leading-edge immunotherapies in the fight against cancer.

Sources:

  • [Source 1: Business Wire, "Pfizer, Moderna, BioNTech and AstraZeneca Lead Off in Mentor's New Medical Investments Portfolio"] https://www.businesswire.com/news/home/20201221005699/en/
  • [Source 2: Mentor Capital, "About Us"] https://www.MentorCapital.com
  • [Source 3: SEC Filings, Mentor Capital, Inc.] https://ir.mentorcapital.com/all-sec-filings

Read more